Holen Sie sich die Stockscreener-App
8.23
0.24%
-0.02
Schlusskurs vom Vortag:
$8.25
Offen:
$8.35
24-Stunden-Volumen:
2.10M
Relative Volume:
1.65
Marktkapitalisierung:
$245.00M
Einnahmen:
$53.74M
Nettoeinkommen (Verlust:
$33.24M
KGV:
3.0903
EPS:
2.6632
Netto-Cashflow:
$-27.40M
1W Leistung:
-6.16%
1M Leistung:
-39.44%
6M Leistung:
+29.00%
1J Leistung:
+297.58%
1-Tages-Spanne:
$8.17
$9.11
1-Wochen-Bereich:
$7.75
$10.40
52-Wochen-Spanne:
$1.905
$23.57
Q 32 Bio Inc Stock (QTTB) Company Profile
Firmenname
Q 32 Bio Inc
Sektor
Branche
Telefon
781-999-0232
Adresse
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
8.23 | 261.08M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | Raymond James | Strong Buy |
| 2024-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-17 | Eingeleitet | Guggenheim | Buy |
| 2024-05-21 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Bestätigt | BTIG Research | Neutral |
| 2022-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-12-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-11-01 | Eingeleitet | Oppenheimer | Perform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Q 32 Bio Inc Aktie (QTTB) Neueste Nachrichten
Oppenheimer reiterates Q32 Bio stock rating on durable trial data By Investing.com - Investing.com Nigeria
Why is Q32 Bio stock sliding today? - Investing.com
Why is Q32 Bio stock surging today? - Investing.com
Q32 Bio presents 36-week SIGNAL-AA Part B results; 35.3% mean SALT reduction, durable off-drug responses - TradingView
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 - PR Newswire
Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 - PR Newswire
Q32 Bio Inc.(NasdaqCM: QTTB) added to S&P Global BMI Index - marketscreener.com
Q32 Bio Inc. (QTTB) Shares Fall 2.95% to $10.54, Sitting at Midpoint of Support and ResistanceReversal Setup Alerts - dars.gov.et
Q32 (QTTB) Drifts Near $10.96 as Market Awaits Catalyst 2026-09-17Rectangle Pattern - dars.gov.et
Cantor Fitzgerald reiterates Q32 Bio stock rating on hair loss data - Investing.com
Q32 Bio Appoints José Trevejo as CMO, Ellie Hershberger as CDO - citybiz
Form 8K Q32 Bio Inc For: 14 September By Investing.com - Investing.com Canada
Q32 Bio appoints new CMO and CDO as it advances alopecia areata drug bempikibart to late-stage trials. - Pluang
QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround - Yahoo Finance
Q32 Bio Inc. (QTTB) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Q32 Bio to present at three major healthcare investor conferences in September 2026 - pluang.com
Q32 Bio to Participate in Upcoming September Investor Conferences - TradingView
Q32 Bio (NASDAQ: FIXX) CFO’s 3,972-share tax sale detailed - Stock Titan
Q32 Bio CFO Lee Kalowski Executes Automatic RSU Tax Withholding Share Sale - Kalkine Media
Q32 Bio CEO Jodie Morrison sells $163,033 in company stock - Investing.com
Q32 Bio CEO Jodie Morrison sells $163,033 in company stock By Investing.com - Investing.com UK
Q32 Bio (FIXX) CEO’s automatic tax sale leaves 343,259 shares - Stock Titan
Q32 Bio: A Deep Dive (NASDAQ:QTTB) - Seeking Alpha
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade - qz.com
Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio Sees Unusually Large Options Volume (NASDAQ:QTTB) - MarketBeat
Q32 (QTTB) Earnings Snapshot: The Bottom-Line Figure Outpaces Its Comparison for the Current Session; Price Move - vinanet.vn
Q32 Bio Company Profile & Introduction - Moomoo
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? - Yahoo Finance
Q32 Bio (NASDAQ:QTTB) stock in focus after mid-stage trial data - Kalkine Media
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB - MarketBeat
Q32 Bio (QTTB) Advances 2.34% as Shares Hold Above Key SupportMean Reversion Trade - vinanet.vn
Q32 Bio (QTTB) Holds Near $15.37 as Shares Consolidate Between Key Support and ResistanceMoney Flow - dars.gov.et
Q32 Bio Inc (NASDAQ: QTTB) Stock Price, News & Analysis - Kalkine
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB) - MarketBeat
Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Q32 Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Q32 Bio tops estimates as alopecia drug advances toward late-stage trials (QTTB:NASDAQ) - Seeking Alpha
Q32 Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Q32 Bio Inc. posts second quarter 2026 results and updates corporate outlook - Traders Union
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) adds $187.6M follow-on cash for AA drug - Stock Titan
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Finanzdaten der Q 32 Bio Inc-Aktie (QTTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Q 32 Bio Inc-Aktie (QTTB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kalowski Lee | CFO and President |
Aug 25 '26 |
Sale |
16.56 |
3,972 |
65,776 |
138,471 |
| Violette Shelia M. | Chief Scientific Officer |
Aug 25 '26 |
Sale |
16.56 |
2,798 |
46,335 |
127,771 |
| Manke Isaac | Director |
Jun 30 '26 |
Option Exercise |
2.80 |
53,521 |
149,859 |
53,521 |
| Xu Diyong | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| ORBIMED ADVISORS LLC | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| Kalowski Lee | CFO and President |
Feb 25 '26 |
Sale |
4.51 |
3,995 |
18,035 |
35,943 |
| Morrison Jodie Pope | CEO |
Feb 25 '26 |
Sale |
4.51 |
9,896 |
44,675 |
89,104 |
| Violette Shelia M. | Chief Scientific Officer |
Feb 25 '26 |
Sale |
4.51 |
2,815 |
12,708 |
55,569 |
| Morrison Jodie Pope | CEO |
Dec 02 '25 |
Sale |
3.46 |
22,506 |
77,871 |
99,000 |
| Kalowski Lee | CFO and President |
Dec 02 '25 |
Sale |
3.46 |
9,072 |
31,395 |
39,938 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):